Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Biomarin Pharmaceutical Inc (BMRN)

549 + Investors. Track Smart Money conviction in BMRN. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +16
Streak
1Q ▲
Buyers last Q
56%

Smart Money Signals — BMRN

Based on 554 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added BMRN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (96% of max)

96% of all-time peak
554 hedge funds hold BMRN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📉

Outflows — 4% fewer funds vs a year ago

fund count last 6Q
25 fewer hedge funds hold BMRN compared to a year ago (-4% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 56% buying

307 buying245 selling
Last quarter: 307 funds bought or added vs 245 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-15 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 88 → 76 → 105 → 90. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

56% of holders stayed for 2+ years

■ 56% conviction (2yr+) ■ 24% medium ■ 20% new
310 out of 554 hedge funds have held BMRN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

106 → 88 → 76 → 105 → 90 new funds/Q
New funds entering each quarter: 88 → 76 → 105 → 90. A growing number of institutions are discovering BMRN each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 63% veterans vs 25% newcomers

■ 63% veterans ■ 12% 1-2yr ■ 25% new
Entry-cohort mix of 576 holders: 362 (63%) are 2+ year veterans, 70 entered 1–2 years ago, and 144 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 60% AUM from top-100 funds

60% from top-100 AUM funds
63 of 551 holders are among the 100 largest funds by AUM, controlling 60% of total institutional value in BMRN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.3
out of 10
Low Exit Risk
Exit risk score 3.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — BMRN

In 2026 Q1, 307 hedge funds were net buyers of BMRN (90 opened a new position, 217 added to an existing one), while 245 reduced or exited (171 trimmed, 74 sold completely) — a 56% buyer ratio, indicating a slight buying edge. 60% of total institutional value in BMRN is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +16 funds (more new holders than closures). Total institutional holders: 554.

Hedge Fund Ownership: BMRN

How many hedge funds hold BMRN — quarterly history vs. share price
Quarterly hedge fund ownership of BMRN vs. share price

Market Analysis: BMRN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: BMRN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Biomarin Pharmaceutical Inc (BMRN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much BMRN has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
BMRN
+17.7%
XLV
+5.5%

BMRN outperformed XLV by +12.2% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
BMRN
+0.0%
XLV
+0.0%

Since the filing became public, BMRN outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

37 top-rated funds 5 high-conviction
Consensus
6.9
/ 10
breadth
×
Elite
3.2
/ 10
conviction
Hedge Fund Positioning: BMRN
2026 Q2 Stats Unlock in 4 days 549 + Investors

Track Smart Money conviction in BMRN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 549 537 2.23%
13F Shares 186M 191M -2.95%
Total Value $10.23B $11.28B -9.36%
New Positions 87 105 -18
Increased Positions 206 168 +38
Closed Positions 75 138 -63
Reduced Positions 163 206 -43
Total Calls 15 17 -11.76%
Total Puts 10 18 -44.44%
PUT/CALL Ratio 0.67 1.06 Bullish

Statistics: BMRN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

549 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BMRN. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 BMRN holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Jones Hill Capital LP 17.42% 1,431,590 $81.9M
2 Vestal Point Capital, LP 8.06% 6,025,000 $344.8M
3 Boone Capital Management LLC 7.81% 583,219 $33.4M
4 Ishara Investments LP 6.03% 143,500 $8.2M
5 Eagle Health Investments LP 5.92% 624,676 $35.7M
6 Defilade Capital Management, L.P. 5.22% 682,005 $39.0M
7 Trails Edge Capital Partners, LP 4.65% 512,000 $29.3M
8 Sector Gamma As 3.66% 294,918 $16.9M
9 Motley Fool Wealth Management, LLC 3.07% 3,533 $202K
10 Deep Track Capital, LP 2.75% 3,307,481 $189.3M
11 Sphera Funds Management LTD. 2.45% 328,550 $18.8M
12 Diadema Partners LP 2.26% 312,846 $17.9M
13 Rhenman & Partners Asset Management AB 1.57% 290,500 $16.6M
14 ARGA Investment Management, LP 1.52% 1,039,409 $59.5M
15 Stonepine Capital Management, LLC 1.46% 50,000 $3.1M
16 Persistent Asset Partners Ltd 1.36% 79,933 $4.6M
17 Viking Global Investors LP 1.24% 7,616,563 $435.8M
18 Sofinnova Investments, Inc. 1.06% 358,568 $20.5M
19 Paragon Capital Management Inc 1.03% 24,200 $1.4M
20 Redmile Group, LLC 1.02% 265,169 $15.2M
21 Easterly Investment Partners LLC 0.96% 329,387 $18.8M
22 Monaco Asset Management SAM 0.84% 184,937 $10.6M
23 Cascade Investment Advisors, Inc. 0.83% 26,465 $1.5M
24 Deerfield Management Company, L.P. 0.80% 1,332,836 $76.3M
25 Privium Fund Management B.V. 0.79% 75,000 $4.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Biomarin Pharmaceutical Inc (BMRN)

What does the Smart Money Trend signal show for BMRN?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added BMRN than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BMRN?

Slight buying edge — 56% buying: Last quarter: 307 funds bought or added vs 245 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for BMRN holders?

Elite ownership — 60% AUM from top-100 funds: 63 of 551 holders are among the 100 largest funds by AUM, controlling 60% of total institutional value in BMRN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held BMRN?

56% of holders stayed for 2+ years: 310 out of 554 hedge funds have held BMRN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Biomarin Pharmaceutical Inc (BMRN) following the 2026 Q2 hedge fund 13F filings?

As of today, BMRN has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BMRN has gained +17.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →